• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals

  • Print
  • Share
  • E-mail
-
Generic Name: self-complementary non-replicating, recombinant adeno-associated virus serotype rhesus 74 expressing the human alpha-sarcoglycan gene under a triple E-box muscle creatine kinase muscle specific promoter (scAAVrh74.tMCK.hSGCA)
Date Designated: 12/05/2018
Orphan Designation: Treatment of limb girdle muscular dystrophy Type 2D
Orphan Designation Status: Designated
FDA Orphan Approval Status: Not FDA Approved for Orphan Indication
Sarepta Therapeutics
215 First Street
Cambridge, Massachusetts 02142
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

*Exclusivity Protected Indications are shown for approvals from 01/01/2013 to the present.
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-
-